Fig 2: ATAD2 is highly expressed in endometrial cancer and correlates with the OS of the patient. (a) TIMER database assessment of ATAD2 expression in pan-cancer. (b) UALCAN-based analysis of ATAD2 mRNA expression in UCEC. (c) Impact of ATAD2 expression in UCEC on patient OS. (d) HPA analysis of ATAD2 protein expression in UCEC. (e, f) UALCAN assessment of ATAD2 and uterine endometrial cancer patients with clinical information correlation. (g) Expression of ATAD2 in human endometrial epithelial cells and four endometrial cancer cell lines. (h) Expression of ATAD2 in endothelial cancer cell lines after overexpression and knockdown of ATAD2.

Fig 3: ATAD2 promotes VEGF expression. (a) TIMER assessment of ATAD2 and VEGF correlation in endometrial cancer. (b) VEGF expression in endometrial cancer cells overexpressing and knocking down ATAD2.

Fig 4: ATAD2 affects the migration and invasion ability of HUVEC. (a) Effect of HEC-1A supernatant as conditioned medium on the migration ability of HUVEC (magnification, 40x). (b) Effect of supernatant of Ishikawa group on the migration ability of HUVEC (magnification, 40x). (c) Quantitative graph of the HEC-1A group scratch experiment. (d) Quantification of scratch experiments in Ishikawa group. (e) Differences in the migration ability of HUVEC cultured under different supernatant conditions (magnification, 100x). (f) Differences in the invasive ability of HUVEC under different groups of conditioned culture (magnification, 100x). (g) Quantitative graph of migration experiments. (h) Quantitative graph of the invasion experiment.

Fig 5: Upregulation of ATAD2 promotes tumor growth and angiogenesis. (a) Transplant tumor growth in mice after injection of ATAD2 overexpression, knockdown, and control of endometrial cancer cells. (b–d) Expression of ATAD2, VEGF, and MVD in knockdown ATAD2 tumors. (e) Mouse transplant tumor growth curve. (f) Immunohistochemical images corresponding to knockdown of ATAD2 (magnification, 200x). (g) The picture of immunohistochemistry of transplanted tumor when ATAD2 was overexpressed above (magnification, 200x). (h–j) Overexpression of ATAD2 increases the expression of VEGF and MVD in transplanted tumor models.